EdenRoc Sciences
Worcester, US · Founded 2016 · Delaware LLC
EdenRoc Sciences is a life sciences holding company that founds and funds subsidiary biotechnology companies addressing diseases of aging, with assets spanning genomic detection, clinical-stage pharmaceuticals, forensics, and biologic-based consumer products. Its subsidiaries operate autonomously while sharing board oversight and centralized business functions, and its work spans diagnostics and therapeutics across biotech and healthcare markets.
Founders & leadership
CW
Christopher WibblemanExecutive
ME
Mathew EasterdayExecutive
CM
Christopher McDonielExecutive
ES
Edward SchulakExecutive
DS
David SinclairNamed on SEC filing
Board
JT
J. Taylor CrandallBoard director
TD
Todd DickinsonBoard director
JA
Jason AndersonBoard director
CB
Carlos BustamanteBoard director
EG
Ed GreenBoard director
Reported raises · per SEC filings
Form D private placements$219.9M disclosed across 10 rounds · 2016–2024
▶$2.8MraisedNov 2024 · 3 investors · BiotechnologyRule 506(b)
▶$2.8MraisedNov 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Edward SchulakExecutive Officer, Director
- Todd DickinsonDirector
- Christopher WibblemanDirector
- J. Taylor CrandallDirector
- Christopher McDonielExecutive Officer
- Mathew EasterdayExecutive Officer
- David SinclairDirector
- Offering amount
- $50M
- Amount sold
- $2.8M
- First sale
- Nov 2024
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$64.2MraisedJul 2024 · 50 investors · BiotechnologyRule 506(b)
▶$64.2MraisedJul 2024 · 50 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher WibblemanDirector
- David SinclairDirector
- J. Taylor CrandallDirector
- Mathew EasterdayExecutive Officer
- Christopher McDonielExecutive Officer
- Edward SchulakExecutive Officer, Director
- Todd DickinsonDirector
- Offering amount
- $64.2M
- Amount sold
- $64.2M
- First sale
- Jun 2022
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$35.9MraisedMay 2022 · 22 investors · BiotechnologyRule 506(b)
▶$35.9MraisedMay 2022 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mathew EasterdayExecutive Officer
- J.Taylor CrandallDirector
- Todd DickinsonDirector
- Edward SchulakExecutive Officer
- David SinclairDirector
- Christopher WibblemanDirector
- Offering amount
- $35.9M
- Amount sold
- $35.9M
- First sale
- May 2021
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$18MraisedNov 2021 · 10 investors · BiotechnologyRule 506(b)
▶$18MraisedNov 2021 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Edward SchulakExecutive Officer, Director
- Carlos BustamanteDirector
- Gregory LucierDirector
- Mathew EasterdayExecutive Officer
- J. Taylor CrandallDirector
- Todd DickinsonDirector
- David SinclairDirector
- Offering amount
- $18M
- Amount sold
- $18M
- First sale
- Aug 2020
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b
▶$17.6MraisedJul 2020 · 11 investors · BiotechnologyRule 506(b)
▶$17.6MraisedJul 2020 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Edward SchulakExecutive Officer, Director
- Carlos BustamanteDirector
- Mathew EasterdayExecutive Officer
- Todd DickinsonDirector
- Jason AndersonDirector
- David SinclairDirector
- Amount sold
- $17.6M
- First sale
- Jan 2020
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b
▶$8MraisedJul 2019 · 4 investors · BiotechnologyRule 506(b)
▶$8MraisedJul 2019 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Edward SchulakExecutive Officer, Director
- Mathew EasterdayExecutive Officer
- Todd DickinsonDirector
- Jason AndersonDirector
- Carlos BustamanteDirector
- David SinclairDirector
- Offering amount
- $47.5M
- Amount sold
- $8M
- First sale
- Jul 2019
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b
▶$13.5MraisedFeb 2019 · 4 investors · BiotechnologyRule 506(b)
▶$13.5MraisedFeb 2019 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mathew EasterdayExecutive Officer
- David SinclairDirector
- Jason AndersonDirector
- Carlos BustamanteDirector
- Todd DickinsonDirector
- Edward SchulakExecutive Officer, Director
- Offering amount
- $13.5M
- Amount sold
- $13.5M
- First sale
- Feb 2019
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b
▶$15MraisedMar 2018 · 2 investors · BiotechnologyRule 506(b)
▶$15MraisedMar 2018 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Carlos BustamanteDirector
- Mathew EasterdayExecutive Officer
- Jason AndersonDirector
- Edward SchulakExecutive Officer, Director
- Todd DickinsonDirector
- David SinclairDirector
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Mar 2018
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
IQVIA15 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Fortis Life Sciences12 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Aro Biotherapeutics11 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Companies competing with EdenRoc Sciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does EdenRoc Sciences do?
- EdenRoc Sciences is a life sciences holding company that founds and funds subsidiary biotechnology companies addressing diseases of aging, with assets spanning genomic detection, clinical-stage pharmaceuticals, forensics, and biologic-based consumer products. Its subsidiaries operate autonomously while sharing board oversight and centralized business functions, and its work spans diagnostics and therapeutics across biotech and healthcare markets.
- How much funding has EdenRoc Sciences raised?
- EdenRoc Sciences has disclosed $219.9M raised across 10 rounds.
- Where is EdenRoc Sciences headquartered?
- EdenRoc Sciences is headquartered in Worcester, US.